Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.15B P/E - EPS this Y -212.80% Ern Qtrly Grth -
Income -132.53M Forward P/E -4.76 EPS next Y 5.80% 50D Avg Chg -12.00%
Sales 377.71M PEG 1.21 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 2.68 EPS next 5Y -3.70% 52W High Chg -61.00%
Recommedations 2.10 Quick Ratio 5.79 Shares Outstanding 82.31M 52W Low Chg 3.00%
Insider Own 1.83% ROA -7.88% Shares Float 73.33M Beta 1.77
Inst Own 87.44% ROE -15.46% Shares Shorted/Prior 13.45M/13.11M Price 28.25
Gross Margin -15.80% Profit Margin -35.09% Avg. Volume 846,674 Target Price 50.00
Oper. Margin 42.02% Earnings Date May 8 Volume 1,381,752 Change -0.91%
About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc. News
04/11/24 Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
03/28/24 Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
03/26/24 Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
03/01/24 Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
02/29/24 News Flash: 11 Analysts Think Beam Therapeutics Inc. (NASDAQ:BEAM) Earnings Are Under Threat
02/28/24 Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
02/28/24 Beam Therapeutics Full Year 2023 Earnings: Beats Expectations
02/27/24 Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
02/27/24 Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
02/27/24 Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ...
02/27/24 Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
02/25/24 Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 13% over the past year
02/20/24 Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
02/16/24 Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
02/15/24 5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
02/10/24 Top 11 CRISPR Stocks To Invest In
02/07/24 3 Biotech Stocks to Buy on the Dip: February 2024
02/05/24 Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/29/24 Why Beam Therapeutics Stock Zoomed 17% Higher Today
01/16/24 Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
BEAM Chatroom

User Image Thestocktraderhubzee Posted - 4 hours ago

WATCHLIST APR 24 2024. $ALHC Stifel Maintains Buy on Alignment Healthcare, Lowers Price Target to $9 $AZZ B. Riley Securities Maintains Buy on AZZ, Raises Price Target to $85 $TRV TD Cowen Maintains Buy on Travelers Companies, Lowers Price Target to $252 $BALY Truist Securities Maintains Buy on Ballys, Raises Price Target to $16 $BEAM Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $57 Price Target

User Image erevnon Posted - 14 hours ago

Wedbush reiterates Beam Therapeutics $BEAM at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image BarneyR Posted - 15 hours ago

$BEAM I've had enough of this shitshow. Neither management nor market makers give a flying fuck about shareholders.

User Image BarneyR Posted - 17 hours ago

$BEAM Oversold for the last three weeks, does anyone care?

User Image BarneyR Posted - 18 hours ago

$BEAM Hey John, maybe you want to offset some of the language in the 10K with the real plan to move forward? Paring expenses so you can afford whatever approval processes and clinical trials are forthcoming? Damn the torpedoes doesn't sit well with investors while the fed hasn't yet committed to interest rate cuts. You're hurting the value of your equity and what leverage you can create with it.

User Image BarneyR Posted - 18 hours ago

$BEAM Beam's 10K has a crazy amount of language describing all risks. Fucking attorneys are the cause. Litigators going after companies for misleading information and litigators defending companies against being sued by including defensive language in public statements that would scare the bejesus out of anyone considering an investment. Problem is, you cannot separate the worst case scenarios outlined from the company's actual plan. Thank America's litigation community for this ridiculous bullshit.

User Image GeneInvestingTwitter Posted - 19 hours ago

$NTLA added 100 yesterday. 3250 $NTLA 3500 $BEAM

User Image Rodmon77 Posted - 21 hours ago

$ALT $ATNM $SGMO $BEAM 👉🏃‍➡️🏃‍➡️💯

User Image BarneyR Posted - 1 day ago

$BEAM Hey, short cretins... don't think Beam is on the right track based on the 10K? Let's hear your reasoning. $1.2B in cash, several meaningful trials underway, a host of constructive alliances, product getting ever closer to submission and approval. Shat upon by visionless Wall Street goons. Come on John, let's give these assholes a ride.

User Image BarneyR Posted - 1 day ago

$BEAM Newly released 2023 10K shows Beam improved its cash position by $100 million between December 31, 2022 and 2023. They have nearly $1.2 billion in cash and equivalents. With enough cash on hand to fund operations through 2027, fed interest rates will have little if any effect on Beam.

User Image PorkyPig Posted - 1 day ago

$BEAM hard to keep up with this stuff: https://www.sec.gov/Archives/edgar/data/1745999/000095017024046028/2024_ars.pdf

User Image BarneyR Posted - 1 day ago

$BEAM Clearly shorts know BEAM has weak defense against its algos, they take advantage of every drop in IXIC and make sure any upswings are blunted. When is BEAM going to spoil their fun? Soon enough.

User Image BarneyR Posted - 1 day ago

$CRSP $BEAM $VERV $NTLA $EDIT Scumbags and their algos are hard work undercutting the value of companies curing deadly diseases. An absolutely reprehensible way to make a living. You can't shower that kind of stink off.

User Image Troy0332 Posted - 3 days ago

$PLD $BEAM $PERI 🗑️ @RedBear

User Image DNAedit Posted - 4 days ago

@PorkyPig completely agree. David Liu and team keep dividing and conquering themselves. It is worse than that. The Chief Science Officer and President of Beam is now working on his next divide (Orbital). Complete crap from these scientists that are spitting out too many companies. In reality they should be one solid company. One HR department. One accounting team, One Investors team, One partnership team, etc... $BEAM $VERV $EDIT

User Image PorkyPig Posted - 4 days ago

$PRME this should have at least been combined with $BEAM but if they had combined $EDIT $BEAM and $PRME into one company with the patents and 2 separate advanced editing technologies under one roof they would be a powerhouse in the industry. Instead... we have 3 shitty individual stocks floundering in the wind, hoovering up cash separately and raising money separately...

User Image Fullratio Posted - 4 days ago

Healthcare sector stocks with high YoY revenue growth in Q4 2023: $FDMT $PAVM $BEAM

User Image Rodmon77 Posted - 4 days ago

$BEAM Got smacked as all Bios have This will recover rather quickly with sector Reversal 🔥

User Image BarneyR Posted - 5 days ago

$BEAM After a 50% cut in share price off recent high, the response to today's green market day is feeble. Come on BEAM, let's cut loose with some positive PR, eh?

User Image SpaceManX9 Posted - 5 days ago

$PRME $CRBU $VERV $NTLA $BEAM Intersting that all of the gene editing stocks have been attacked since February 27. Definitely a coordinated effort to force all of the market caps down. Someone is also buying several hundred thousand shares of each of the gene editing stocks at the end of the trading day. This has been going on for months. Any thoughts on something that might have triggered the decline starting on February 27?

User Image stuntman9883 Posted - 6 days ago

$BEAM accumulation time https://vm.tiktok.com/ZGeHAedj9/

User Image GeneInvestingTwitter Posted - 6 days ago

$NTLA $BEAM Down 40% overall in 6/7 weeks That is $100k down in 1.5 months boys and girls. So much fun.

User Image BarneyR Posted - 6 days ago

$BEAM Market Makers in this and other gene therapy concerns are pigs at the trough, making bank on the misery of companies and their shareholders.

User Image BarneyR Posted - 6 days ago

$BEAM -5% just on general principle. Because these companies curing diseases deserve rough treatment by classless, conscious less assholes eager to earn their next Lambo or beach house.

User Image BarneyR Posted - 6 days ago

$BEAM Has now lost 50% of its value from recent intraday high of $49.50. Naked Wall Street fuckery.

User Image zongju1988 Posted - 1 week ago

$NTLA $CRSP $BEAM Hi guys, is gene editing really technically feasible? The entire sector is underperforming since post pandemic.

User Image MagisterofMarkets Posted - 1 week ago

$NTLA $CRBU $CRSP $BEAM $VERV give me a fucking break

User Image BarneyR Posted - 1 week ago

$CRSP $BEAM $NTLA $EDIT $VERV Share price isn't a function of fundamentals, performance or prospects, it's about the value algos can squeeze out of momentum in either direction. There's no catalysts in gene therapy presently to cause concern for scumbags who see no downside in forcing a share price lower, for profit. This is the sort of manipulation that gives the stock market a putrid smell. And the manipulators don't care because this isn't about investing in value, it's about making money. Sickening to watch.

User Image KabraxisX Posted - 1 week ago

$CRSP $BEAM and $NTLA

User Image St0ckt0k101 Posted - 1 week ago

$BEAM strong support at $21 folks! Not going much lower, start buying this week, RSI just below 30! ✅💯🎯

Analyst Ratings
Wedbush Outperform Apr 23, 24
BMO Capital Outperform Mar 27, 24
Barclays Equal-Weight Feb 28, 24
RBC Capital Sector Perform Feb 28, 24
JP Morgan Overweight Jan 29, 24
B of A Securities Neutral Dec 15, 23
Jefferies Hold Dec 8, 23
Cantor Fitzgerald Overweight Oct 17, 23
Cantor Fitzgerald Overweight Sep 13, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Simon Amy Chief Medical Office.. Chief Medical Officer Jul 10 Sell 30.48 391 11,918 68,917 08/09/23
Ciaramella Giuseppe President and CSO President and CSO Jul 21 Sell 32.04 156,530 5,015,221 48,250 07/25/23
Ciaramella Giuseppe President and CSO President and CSO Jul 21 Option 7.22 92,490 667,778 49,456 07/25/23
Evans John M. CEO CEO Apr 03 Sell 29.7 11,654 346,124 1,117,979 04/05/23
Ciaramella Giuseppe President & CSO President & CSO Apr 03 Sell 29.7 3,672 109,058 112,290 04/05/23
Bellon Christine Chief Legal Officer Chief Legal Officer Apr 03 Sell 29.7 2,092 62,132 82,790 04/05/23
Simon Amy Chief Medical Office.. Chief Medical Officer Apr 03 Sell 29.72 16,099 478,462 69,308 04/05/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Apr 03 Sell 29.7 4,640 137,808 47,117 04/05/23
Bellon Christine Chief Legal Officer Chief Legal Officer Mar 30 Option 7.22 8,941 64,554 67,382 03/31/23
Evans John M. CEO CEO Jan 31 Option 7.22 13,850 99,997 1,129,153 03/31/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Jan 23 Sell 45.02 20,236 911,025 31,277 01/25/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Jan 23 Option 13.68 20,236 276,828 46,087 01/25/23
Ciaramella Giuseppe President & CSO President & CSO Dec 12 Option 2.45 26,863 65,814 142,477 12/14/22
Ciaramella Giuseppe President & CSO President & CSO Dec 12 Sell 43.11 51,015 2,199,257 91,462 12/14/22
FMR LLC 10% Owner 10% Owner Sep 06 Sell 54.25 551 29,892 09/08/22
FMR LLC 10% Owner 10% Owner Aug 04 Sell 60.75 20,326 1,234,804 08/08/22
Evans John M. CEO CEO Apr 28 Option 4.13 59,450 245,528 1,148,520 05/02/22
Evans John M. CEO CEO Apr 28 Sell 38.68 50,000 1,934,000 143,000 05/02/22
FMR LLC 10% Owner 10% Owner Apr 12 Sell 50.57 19,466 984,396 04/14/22
Ciaramella Giuseppe President & CSO President & CSO Mar 31 Sell 59.11 1,859 109,885 115,614 04/04/22
Evans John M. CEO CEO Mar 31 Sell 59.11 6,261 370,088 1,089,070 04/04/22
Burrell Terry-Ann CFO CFO Mar 31 Sell 59.11 1,787 105,630 38,278 04/04/22
Evans John M. CEO CEO Jan 31 Option 1.03 100,000 103,000 1,038,825 02/02/22
Evans John M. CEO CEO Jan 31 Sell 65.95 50,000 3,297,500 163,000 02/02/22
Ciaramella Giuseppe President & CSO President & CSO Dec 20 Option 7.22 29,393 212,217 87,877 12/22/21
Ciaramella Giuseppe President & CSO President & CSO Dec 20 Sell 85.62 29,393 2,516,629 62,773 12/22/21
Ciaramella Giuseppe President & CSO President & CSO Apr 02 Option 0.67 4,030 2,700 19,761 04/02/21
Ciaramella Giuseppe President & CSO President & CSO Jan 04 Option 0.85 55,842 47,466 15,731 01/04/21
Ciaramella Giuseppe President & CSO President & CSO Jan 04 Sell 84.14 43,842 3,688,866 3,731 01/04/21
Evans John M. CEO CEO Jan 04 Sell 85.39 22,300 1,904,197 970,957 01/04/21